Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 2/20 | 0.42 |
| ▸ | MC3R | P41968 | 2/20 | 0.42 |
| ▸ | MC1R | Q01726 | 1/20 | 0.42 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.41 |
| ▸ | BDKRB2 | P30411 | 2/20 | 0.39 |
| ▸ | CFD | P00746 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 2/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.37 |
| ▸ | CA5A | P35218 | 1/20 | 0.37 |
| ▸ | XIAP | P98170 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13164550 | 0.78 | MC4R (0.46) | MC4RMC3RMC1RAGTR2CFD | |
| SCHEMBL13746928 | 0.74 | XIAP (0.55) | XIAP | |
| SCHEMBL13164553 | 0.74 | XIAP (0.55) | XIAP | |
| SCHEMBL13164549 | 0.73 | ABCB1 (0.52) | MC4RMC3RMC1RCYP3A4MAPT | |
| SCHEMBL13164551 | 0.73 | ELANE (0.52) | MC4RMC3RMC1RXIAP | |
| SCHEMBL13164552 | 0.70 | XIAP (0.43) | MC4RMC3RMC1RAGTR2XIAP | |
| SCHEMBL7245592 | 0.69 | APP (0.56) | APPMMP3 | |
| SCHEMBL11205534 | 0.69 | AGTR2 (0.57) | AGTR2BDKRB2 | |
| SCHEMBL11205530 | 0.69 | AGTR2 (0.57) | AGTR2BDKRB2 | |
| SCHEMBL11205539 | 0.69 | AGTR2 (0.57) | AGTR2BDKRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232985-A1 | Succinoylamino heterocycles as inhibitors of a beta protein production | THOMPSON LORIN A (US) | 2003-12-18 | — | — | US | disclosed |
| US-20030073701-A1 | Succinoylamino heterocycles as inhibitors of a beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073701-A1 | Succinoylamino heterocycles as inhibitors of a beta protein production | APP, BACE1, APH1A | MC4R 4528/4885MC3R 4722/4885MC1R 3788/4885 |
| US-20030232985-A1 | Succinoylamino heterocycles as inhibitors of a beta protein production | APP, BACE1, APH1A | MC4R 4528/4885MC3R 4722/4885MC1R 3788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.